Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.

Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.

Provided is an ink composition for use in drop on demand inkjet printing such as piezoelectric drop on demand inkjet printing. The ink composition has a phosphine oxide initiator and benzyl acrylate. The amount of benzyl acrylate is less than 40 wt % based on the total weight of the ink composition and the total amount of mono-functional monomers is less than 45 wt % based on the total weight of the ink composition. The phosphine oxide initiator is a bis-acyl phosphine oxide, a benzoyl alkyl phosphinate, or a mixture thereof. The ink compositions are suitable for radiation curing and have good cure properties or good adhesion properties.

The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable pharmaceutical composition and may be used, for example, to treat eubicarbonatemic metabolic acidosis.

The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable pharmaceutical composition and may be used, for example, to treat eubicarbonatemic metabolic acidosis.

A crosslinkable rubber composition, comprising: an acrylic rubber; an amine compound represented by the following formula (A-1); a carbon black; and a crosslinking agent, wherein the acrylic rubber has acrylate units and carboxy group-containing monomer units, and has 0.5 to 10 parts by mass of ethylene units with respect to 100 parts by mass of the acrylate units and/or 5 to 20 parts by mass of alkyl methacrylate units with respect to 100 parts by mass of the acrylate units,

##STR00001## wherein R.sup.1 represents a hydrogen atom or an amino group in the formula (A-1).

A crosslinkable rubber composition, comprising: an acrylic rubber; an amine compound represented by the following formula (A-1); a carbon black; and a crosslinking agent, wherein the acrylic rubber has acrylate units and carboxy group-containing monomer units, and has 0.5 to 10 parts by mass of ethylene units with respect to 100 parts by mass of the acrylate units and/or 5 to 20 parts by mass of alkyl methacrylate units with respect to 100 parts by mass of the acrylate units,

##STR00001## wherein R.sup.1 represents a hydrogen atom or an amino group in the formula (A-1).

Copolymer compositions and methods of making copolymer compositions with enhanced stability in high temperature and high salinity environments. The copolymers include hydrophobic monomers and sulfonated monomers. The sulfonated monomers can include 2-acrylamido-2-methylpropane sulfonic acid and allyl sulfonate. The sulfonated monomers increase the stability of the polymers in harsh conditions, and in high temperature, high salinity environments. The sulfonated monomers also reduce or prevent the hydrolysis of acrylamide groups, and therefore enhance the stability of the copolymer. The copolymer compositions can be made with free radical polymerization and an initiation complex.

Copolymer compositions and methods of making copolymer compositions with enhanced stability in high temperature and high salinity environments. The copolymers include hydrophobic monomers and sulfonated monomers. The sulfonated monomers can include 2-acrylamido-2-methylpropane sulfonic acid and allyl sulfonate. The sulfonated monomers increase the stability of the polymers in harsh conditions, and in high temperature, high salinity environments. The sulfonated monomers also reduce or prevent the hydrolysis of acrylamide groups, and therefore enhance the stability of the copolymer. The copolymer compositions can be made with free radical polymerization and an initiation complex.